Form 4: Seres Therapeutics Director Woerle Granted Stock Options
SEC Form 4 Filing
Director Hans-Juergen Woerle receives stock options from Seres Therapeutics.
Summary
- Hans-Juergen Woerle, a director of Seres Therapeutics, Inc., was granted stock options on February 4, 2025.
- The stock options allow Woerle to purchase 120,000 shares of common stock at an exercise price of $0.8056 per share.
- The options vest in four equal installments annually starting February 4, 2025, or fully upon a change in control, and expire on February 3, 2035.
- Following the transaction, Woerle directly owns 120,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's success.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. This is a standard practice.
Comparison to Industry Standards
- Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
- The vesting schedule of four years is also a common practice to ensure long-term commitment.
- Comparable companies such as Moderna, BioNTech, and Novavax also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign of aligning director interests with company performance.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/04/2025 | Date of the stock option grant and first vesting anniversary. |
| 02/03/2035 | Expiration date of the stock options. |
| 02/06/2025 | Date of signature on the Form 4 filing. |
Keywords
stock options, director, Seres Therapeutics, MCRB, beneficial ownership, Form 4, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.